Soligenix (SNGX) Projected to Post Earnings on Friday

Soligenix (NASDAQ:SNGX) is expected to be posting its Q3 2026 resultson Friday, November 6th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Soligenix (NASDAQ:SNGX) last posted its earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. On average, analysts expect Soligenix to post ($0.55) EPS for the current fiscal year and ($0.40) EPS for the next fiscal year.

Soligenix Price Performance

SNGX stock opened at $0.36 on Wednesday. The stock has a market capitalization of $5.28 million, a P/E ratio of -0.36 and a beta of 2.04. Soligenix has a 1-year low of $0.28 and a 1-year high of $1.70. The business has a fifty day moving average price of $0.37 and a 200-day moving average price of $0.68.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Soligenix presently has a consensus rating of “Sell”.

Soligenix Company Profile

Soligenix, Inc is a U.S.-based biopharmaceutical company focused on developing treatments for rare diseases and serious medical conditions with limited therapeutic options. The company’s programs are primarily aimed at immunology, inflammation, infectious diseases and oncology, with an emphasis on advancing candidates through clinical development and regulatory approval.

Soligenix’s pipeline has included SGX301, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma; SGX942, an innate defense regulator investigated for inflammatory conditions such as oral mucositis; and SGX945, a related candidate studied for Behçet’s disease.